Surrozen is a biotechnology company founded in 2016 with a focus on discovering and developing novel regenerative medicines through specific control of the Wnt signaling pathway. Founded by eminent scientists from Stanford University, the Princess Maxima Center for Pediatric Oncology, and the Hubrecht Institute, the company benefits from the extensive research on Wnt signaling conducted by these experts. It is headquartered in the United States and is backed by leading biotechnology venture capital firm, The Column Group.
The most recent investment in Surrozen was a significant $17.50M Post-IPO Equity investment on 01 April 2024. This investment was made by a consortium of notable investors including RA Capital Management, The Column Group, Stonepine Capital Management, StemPoint Capital, and Nantahala Capital Management.
Surrozen's dedication to leveraging the body's self-renewal properties and the substantial support from prominent investors makes it a compelling player in the biotechnology and healthcare industries. As the company continues to expand, it aims to attract highly creative scientists to contribute to its pioneering work in the field of regenerative medicine.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $17.50M | 5 |
|
01 Apr 2024 |
| Post-IPO Equity | $120.00M | 2 |
|
12 Aug 2021 |
| Series C | $50.00M | 3 |
|
19 Jun 2020 |
| Series B | $50.00M | - | 15 Mar 2019 | |
| Series A | $33.00M | - | 15 Feb 2017 |
No recent news or press coverage available for Surrozen.
We care about your data, and we'd love to use cookies make your experience better.
